Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

May 31, 2000

Primary Completion Date

August 31, 2005

Conditions
Endometrial Cancer
Interventions
DRUG

pegylated liposomal doxorubicin hydrochloride

Trial Locations (10)

27710

Duke Comprehensive Cancer Center, Durham

37203

Brookview Research, Inc., Nashville

63110

Washington University School of Medicine, St Louis

92868

Chao Family Comprehensive Cancer Center, Orange

46202-5289

Indiana University Cancer Center, Indianapolis

52242-1009

Holden Comprehensive Cancer Center, Iowa City

02111

New England Medical Center Hospital, Boston

39216-4505

University of Mississippi Medical Center, Jackson

27157-1082

Comprehensive Cancer Center at Wake Forest University, Winston-Salem

43210-1240

Arthur G. James Cancer Hospital - Ohio State University, Columbus

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT00005861 - Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer | Biotech Hunter | Biotech Hunter